Restoring Function Saving Lives
We are dedicated to curing and preventing medical device-related infection – a devastating and, too often, life-threatening condition affecting millions across the world.
Company
Peptilogics is a surgical therapeutics company advancing a novel anti-biofilm drug designed to cure and prevent all medical device-related infections.
Pipeline
Peptilogics’ clinical stage pipeline is led by PLG0206, a novel anti-biofilm therapeutic, currently enrolling the pivotal Ph2/3 RETAIN trial for the treatment of devastating prosthetic joint infections (PJI), for which there are no approved therapies. PLG0206 has Orphan Disease Designation from the FDA, Fast Track and QIDP status.